• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TLS-CHOP 抑制 miR-486 的表达,诱导人黏液样脂肪肉瘤中转移调节因子 PAI-1 的上调。

TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma.

机构信息

Department of Molecular Pathology, Tokyo Medical University, Tokyo 160-8402, Japan.

出版信息

Biochem Biophys Res Commun. 2012 Oct 19;427(2):355-60. doi: 10.1016/j.bbrc.2012.09.063. Epub 2012 Sep 18.

DOI:10.1016/j.bbrc.2012.09.063
PMID:22995304
Abstract

Myxoid liposarcomas (MLSs) are characterized by t(12;16)(q13;p11) translocation and expression of TLS-CHOP chimeric oncoprotein. However, the molecular functions of TLS-CHOP have not been fully understood. On the other hand, microRNAs (miRNAs) comprise an abundant class of endogenous small non-coding RNAs that negatively regulate the expression of their target genes, and are involved in many biological processes. It is now evident that dysregulation of miRNAs is an important step in the development of many cancers. To our knowledge, however, there have been no reports of the miRNAs involved in MLS tumorigenesis and development. In this study, we have found that miR-486 expression was repressed in TLS-CHOP-expressed NIH3T3 fibroblasts and MLS tissues, and exogenous overexpression of miR-486 repressed growth of MLS cells. Thus, downregulation of miR-486 may be an important process for MLS. In addition, we have identified plasminogen activator inhibitor-1 (PAI-1) as a novel target gene of miR-486. PAI-1 is a unique type of serine protease inhibitor and is known to be one of the key regulators of tumor invasion and metastasis. Furthermore, knockdown of PAI-1 by a specific small interfering RNA (siRNA) inhibited growth of MLS cells, suggesting that increased expression of PAI-1 by miR-486 repression is critical for survival of MLS cells. Collectively, these results suggest a novel essential molecular mechanism that TLS-CHOP activates PAI-1 expression by repression of miR-486 expression in MLS tumorigenesis and development.

摘要

黏液样脂肪肉瘤(MLSs)的特征是 t(12;16)(q13;p11) 易位和 TLS-CHOP 嵌合癌蛋白的表达。然而,TLS-CHOP 的分子功能尚未完全了解。另一方面,microRNAs(miRNAs)是一类丰富的内源性小非编码 RNA,它们负调控其靶基因的表达,并参与许多生物学过程。现在很明显,miRNAs 的失调是许多癌症发展的重要步骤。然而,据我们所知,尚未有报道涉及 miRNA 参与 MLS 的肿瘤发生和发展。在这项研究中,我们发现 miR-486 的表达在 TLS-CHOP 表达的 NIH3T3 成纤维细胞和 MLS 组织中受到抑制,外源性过表达 miR-486 抑制 MLS 细胞的生长。因此,miR-486 的下调可能是 MLS 的一个重要过程。此外,我们已经确定了纤溶酶原激活物抑制剂-1(PAI-1)是 miR-486 的一个新的靶基因。PAI-1 是一种独特类型的丝氨酸蛋白酶抑制剂,是已知的肿瘤侵袭和转移的关键调节因子之一。此外,特异性小干扰 RNA(siRNA)敲低 PAI-1 抑制 MLS 细胞的生长,表明 miR-486 抑制导致 PAI-1 表达增加对 MLS 细胞的存活至关重要。总之,这些结果表明了一种新的重要分子机制,即 TLS-CHOP 通过抑制 miR-486 的表达来激活 PAI-1 的表达,从而促进 MLS 的肿瘤发生和发展。

相似文献

1
TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma.TLS-CHOP 抑制 miR-486 的表达,诱导人黏液样脂肪肉瘤中转移调节因子 PAI-1 的上调。
Biochem Biophys Res Commun. 2012 Oct 19;427(2):355-60. doi: 10.1016/j.bbrc.2012.09.063. Epub 2012 Sep 18.
2
A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression.TLS-CHOP 介导的新型致癌通路,涉及 MDA-7/IL-24 表达的抑制。
Br J Cancer. 2012 Jun 5;106(12):1976-9. doi: 10.1038/bjc.2012.199. Epub 2012 May 15.
3
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.P53状态、TLS-CHOP融合转录本结构及组织学分级对黏液样脂肪肉瘤的预后影响:82例分子及临床病理研究
Clin Cancer Res. 2001 Dec;7(12):3977-87.
4
Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.原发性间充质祖细胞中FUS-CHOP融合蛋白的表达产生了黏液样脂肪肉瘤模型。
Cancer Res. 2006 Jul 15;66(14):7016-23. doi: 10.1158/0008-5472.CAN-05-3979.
5
Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.嵌合型 TLS/FUS-CHOP 基因表达及其在人黏液样和圆形细胞脂肪肉瘤中连接区的异质性
Am J Pathol. 1995 Nov;147(5):1221-7.
6
Detection of TLS/FUS-CHOP fusion transcripts in a case of oral liposarcoma.一例口腔脂肪肉瘤中TLS/FUS-CHOP融合转录本的检测
Ann Diagn Pathol. 2006 Feb;10(1):36-8. doi: 10.1016/j.anndiagpath.2005.04.006.
7
Generation of the novel monoclonal antibody against TLS/EWS-CHOP chimeric oncoproteins that is applicable to one of the most sensitive assays for myxoid and round cell liposarcomas.针对TLS/EWS-CHOP嵌合癌蛋白生成新型单克隆抗体,该抗体适用于黏液样和圆形细胞脂肪肉瘤最敏感的检测方法之一。
Am J Surg Pathol. 2006 Mar;30(3):351-6. doi: 10.1097/01.pas.0000194043.01104.eb.
8
Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.FUS-DDIT3 型黏液样脂肪肉瘤中 FLT1 的核表达及其配体 PGF 提示存在一个内源性信号环路。
BMC Cancer. 2010 Jun 1;10:249. doi: 10.1186/1471-2407-10-249.
9
Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia.黏液样脂肪肉瘤和急性髓性白血病中融合基因FUS/CHOP、EWS/CHOP和FUS/ERG断点处的特征性序列基序。
Oncogene. 1997 Sep;15(11):1357-62. doi: 10.1038/sj.onc.1201281.
10
Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis.FUS-CHOP通过miR-486/CDK4轴在黏液样脂肪肉瘤中的作用
Biochem Genet. 2022 Jun;60(3):1095-1106. doi: 10.1007/s10528-021-10151-x. Epub 2021 Nov 18.

引用本文的文献

1
Deciphering the roles of non-coding RNAs in liposarcoma development: Challenges and opportunities for translational therapeutic advances.解读非编码RNA在脂肪肉瘤发生发展中的作用:转化治疗进展面临的挑战与机遇
Noncoding RNA Res. 2024 Nov 15;11:73-90. doi: 10.1016/j.ncrna.2024.11.005. eCollection 2025 Apr.
2
Dysregulation of miRNAs in Soft Tissue Sarcomas.软组织肉瘤中 miRNAs 的失调。
Cells. 2024 Nov 8;13(22):1853. doi: 10.3390/cells13221853.
3
FUS::DDIT3 Fusion Protein in the Development of Myxoid Liposarcoma and Possible Implications for Therapy.
FUS::DDIT3 融合蛋白在黏液样脂肪肉瘤的发生发展中的作用及其对治疗的可能影响。
Biomolecules. 2024 Oct 14;14(10):1297. doi: 10.3390/biom14101297.
4
Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.用于靶向治疗选择的脂肪肉瘤中的遗传、表观遗传和转录组改变
Cancers (Basel). 2024 Jan 8;16(2):271. doi: 10.3390/cancers16020271.
5
Suppression of antitumor cytokine IL‑24 by PRG4 and PAI‑1 may promote myxoid liposarcoma cell survival.PRG4和PAI-1对抗肿瘤细胞因子IL-24的抑制作用可能促进黏液样脂肪肉瘤细胞的存活。
Biomed Rep. 2023 Jul 26;19(3):60. doi: 10.3892/br.2023.1642. eCollection 2023 Sep.
6
MicroRNAs in the Pathogenesis, Prognostication and Prediction of Treatment Resistance in Soft Tissue Sarcomas.微小RNA在软组织肉瘤发病机制、预后及治疗耐药预测中的作用
Cancers (Basel). 2023 Jan 18;15(3):577. doi: 10.3390/cancers15030577.
7
Posttranscriptional Regulation of the Plasminogen Activation System by Non-Coding RNA in Cancer.非编码 RNA 对癌症纤溶酶原激活系统的转录后调控
Int J Mol Sci. 2023 Jan 4;24(2):962. doi: 10.3390/ijms24020962.
8
miR-486-5p expression is regulated by DNA methylation in osteosarcoma.miR-486-5p 的表达受骨肉瘤中 DNA 甲基化的调控。
BMC Genomics. 2022 Feb 17;23(1):142. doi: 10.1186/s12864-022-08346-6.
9
Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level.软组织肉瘤:分子、代谢和细胞水平生物标志物的见解
Cancers (Basel). 2021 Jun 18;13(12):3044. doi: 10.3390/cancers13123044.
10
Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment.脂肪肉瘤:细胞与分子遗传学改变及相应临床治疗的进展
J Cancer. 2020 Jan 1;11(1):100-107. doi: 10.7150/jca.36380. eCollection 2020.